Cardene SR



	Significantly improves hemodynamics¹* Click here for a printer friendly version. \| Click here for important safety information. Cardene SR is indicated for the treatment of hypertension. Decreases blood pressure at rest and during exercise Systolic and diastolic blood pressure decreases during the dosing interval Significantly reduces systemic vascular resistance (SVR) Improved left ventricular (LV) diastolic distensibility during the early filling stage No negative effect on myocardial relaxation at therapeutic doses No evidence of coronary steal No detrimental effects on the cardiac conduction system Reaches peak plasma levels at 1 to 4 hours¹ Patients with mild renal impairment showed plasma levels similar to those with normal renal function Patients with severe liver disease or moderate renal function developed elevated blood levels Can be used alone or in combination with other antihypertensive drugs¹ Safe with thiazide diuretics Safe with β-blockers As measured by increased ejection fraction and cardiac output. References* CARDENE SR [prescribing information]. Redwood City, Calif: PDL BioPharma, Inc; 2007.

Important Safety Information
CARDENE SR is contraindicated in patients with known hypersensitivity to the drug and in patients with advanced aortic stenosis. Reduction of diastolic pressure by any means in these patients may worsen rather than improve myocardial oxygen balance. Caution is advised when administering Cardene SR to patients with angina, congestive heart failure (particularly those who are also taking a ß-blocker), impaired renal or hepatic function, or severe left ventricular dysfunction. Cardene SR provides no protection against the dangers of abrupt ß-blocker withdrawal. The immediate release form of nicardipine caused an increase in angina in 7% of patients compared to 4% on placebo. The most common adverse events were headache (6.2%), pedal edema (5.9%), vasodilation (4.7%), increased angina (4%), palpitation (2.8%), nausea (1.9%), and dizziness (1.6%). Cyclosporine levels should be monitored closely during therapy.

Makers of

and